



A BREAKTHROUGH IN A MULTIBILLION-DOLLAR NICH: KIDNEY PROTECTION

THE PROBLEM: THE SILENT EPIDEMIC

Antibiotics save lives, but they cause widespread damage. Up to **60%** of Acute Kidney Injury (AKI) cases are linked to nephrotoxic drug use.

Current Situation= Classic Catch-22:

- All life-threatening bacterial infections require aggressive antibiotic treatment (e.g., polymyxins, aminoglycosides, vancomycin).
- The antibiotic must be "STRONG" to kill the bacteria — but that very strength destroys the kidneys.
- The antibiotic must be "NON-STRONG", not to harm the kidneys, but then it fails to eliminate the bacteria.

ZERO drugs on the market are approved to protect the kidneys from antibiotic toxicity directly.

This represents a vast, unaddressed **UNMET MEDICAL NEED** and a true **multi-billion-dollar blue-ocean opportunity**.


OUR SOLUTION: NephroFortis®

The Universal Off-Switch for Drug-Induced Nephrotoxicity

The "MUSICAL CHAIRS" Principle

We introduce a novel drug, "NephroFortis®," that physically protects kidney cells at the molecular level from severe antibiotic toxins.

Solution: Our Protector fills Kidney Spaces, protecting them from Antibiotic damage
(Like musical chairs).



CORE MECHANISM (The Musical Chairs)

Protector temporarily fills the key receptors, megalin, in the kidneys. When antibiotic toxins enter the body, there is **"no room"** left for them, and they

are safely excreted without causing harm.

VALIDATION AND IP MOAT

A True Blue Ocean Market

While billions are invested in protective care, this niche is wide open. Our Universal Nephroprotectors are designed for co-administration with ALL major nephrotoxic antibiotics and anti-cancer drugs.

IP & PoC Highlights

Feature	Details
IP Protection	US Patent Granted: US Patent No. 11,191,806, expired 2038 (A strong, defensible position). Total Portfolio: 220+ patents (including 10 US grants).
Effectiveness	Pre-Clinical PoC: Animal studies show a significant reduction in kidney damage (AKI) and preserved renal function.
Superior Properties	NephroFortis has a higher affinity to the megalin receptor than Polymyxin antibiotics and does not affect the antibiotic's primary antimicrobial activity.

TRIZ Biopharma Innovations applies a unique approach as the only company using TRIZ (Theory of Inventive Problem Solving) to address pharmaceutical challenges, enabling robust, non-obvious intellectual property.

Visionary Leadership and Proven Execution

Dr. Boris Farber, CEO, Founder, & Lead Inventor

Strong Experienced Team. **Proven track record** of grants, patents, publications, and implementation through mass production, supported by seasoned regulatory and business development experts.

Two Already Licensed Drugs: Albuvir and Gema-D (licensed and manufactured).

INVESTMENT PROPOSAL: NEPHROFORTIS ASSET

Solving the Medical Catch-22

How to destroy a deadly infection while simultaneously saving the kidneys.

Financing Request

ROUND: \$6 Million GOAL: Funding required to reach IND Filing for clinical trials.

- GLP Toxicology/Activity Studies.
- GMP Manufacturing Preparation.
- IND Filing (Clinical Trial Approval).

Potential Returns (15 Months Outlook)

Milestone	Timeline	Valuation
Current (pre-seed)	Q2 2026	\$6 M

Milestone	Timeline	Valuation
IND filed	Q1 2027	\$30 M
First human AKI data	Q2–Q4 2027	\$100 M+

INVESTMENT HIGHLIGHTS – \$3.2 M Seed Round

Pre-money valuation	\$6 – 10 M
Post-money valuation	\$9 – 13 M
Use of funds	IND filing in 18–24 months
Exit trigger	First human AKI data (Phase 1/2a)
Target exit valuation	\$200 – 500 M+ M&A
Investor ROI (MOIC)	25 – 60×
Annualized IRR	150 – 300 % (18–30 months)
Comparables	Chinook \$3.2 B · Travere \$1.2 B Renibus \$500 M · Regulus \$0.8–1.7 B

\$3.2 M invested today → \$80 – 200 M+ return at exit

Investor Card (Seed Round Snapshot)

ROI (MOIC): 25–60× · IRR: 150–300% (18–30 months) · Exit

Valuation: \$200–500 M+

FINANCIAL SECURITY & PROFITABILITY

Metric	Value	Investor Impact
Gross Margin (GM)	~99%	Achieved through low Cost of Goods Sold (COGS).
TAM	\$200–250B – global AKI/CKD treatment/correction market (dialysis, drugs, hospitalizations)	Massive target market with no direct competitors.
SAM/SOM	SAM: \$160B / SOM: \$25B (Nephrotoxic polymyxins and anticancer)	

VAST UNIVERSAL MARKET

The potential market is far broader than just antibiotics, including all high-volume nephrotoxic drugs.

Market Size (Addressable Segments)

Our technology eliminates nephrotoxicity in commonly used, high-revenue drug classes:

1. Nephrotoxic Antibiotics: Peptide Antibiotics (Polymyxins), Aminoglycosides (Gentamycin, Amikacin), Polyene Antibiotics (Amphotericin), Tricyclic Glycopeptides (Vancomycin)

2. Nephrotoxic Anticancer Drugs (additional preclinical studies are planned):

Platinum Derivatives: \$2 Bln Market

Immune Checkpoint Inhibitors: \$27Bln Market

Alkylating Agents: \$14 Bln Market

This universal approach allows us to target multiple multi-billion-dollar therapeutic areas simultaneously.

Potential Returns – 18–24 Months

Target Exit \$200–500 M+ M&A with Big Pharma (comps: Chinook \$3.2 B, Travere/Vifor \$1.2 B, Renibus/Bayer \$500 M)

CALL TO ACTION

Let's Conquer this Unique Unmet Niche Multi-Billion-Dollar Market Together!

OUR UNIQUE TRIZ INNOVATION PLATFORM

The application of the TRIZ methodology is the key differentiator, enabling us to pioneer:

- Universal Nephroprotection Strategies in MDR Fighting Therapies.
- A new generation of **Dynamic, Self-Personalized, Adapting Medical Drugs.**

Our proprietary technology is designed to eliminate the trade-off between fighting infection and preserving organ health.

NEXT STEP

We welcome strategic partners to help develop our Universal Nephroprotectors platform.


Let's Conquer this Unique Unmet Multi-Billion-Dollar Market together!

LEADERSHIP: PROVEN EXECUTION

CONTACT US: Dr. Boris Farber, CEO

drfarber@trizbiopharma.com +1(646) 248-2880
<https://www.linkedin.com/in/dr-boris-farber-0309b6121/>

Website: www.trizbiopharma.com



Video 1: "Novel Nephroprotection"

Video 2: "Dynamic Self-Adapting Medicines"

